No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3)


1Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France; 2Department of Epidemiology and Biostatistics, Imperial College London, London, UK; 3Cancer Epidemiology Center, Cancer Council Victoria, Melbourne; 4Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia; 5MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK; 6Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, USA; 7Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; 8Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, USA; 9K.G. Jebsen Center for Genetic Epidemiology, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 10Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA; 11Harvard Medical School, Boston; 12Department of Epidemiology, Richard M. Fairbanks School of Public Health, Emory University, Atlanta; 13Department of Biostatistics, Indiana University, Indianapolis; Departments of 14Epidemiology, 15Nutrition, Harvard T.H. Chan School of Public Health, Boston; Divisions of 16Aging, 17Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston; 18Boston VA Medical Center, Boston; 19Epidemiology Research Program, American Cancer Society, Atlanta; 20Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle; 21Department of Public Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; 22Department of Epidemiology, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai; 23State Key Laboratory of Oncogene and Related Genes, Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 24Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville; 25UPMC Hillman Cancer Center; 26Division of Public Health, University of Pittsburgh, Pittsburgh, USA; 27Duke-NUS Graduate Medical School Singapore, Singapore; 28Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, USA; 29Laboratory of Clinical Biochemistry, Department of Clinical Science, University of Bergen, Bergen, Norway; 30Haukeland University Hospital, Bergen; 31Bevtal AS, Bergen; 32Department of Public Health and Nursing, HUNT Research Center, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Levanger, Norway; 33Department of Radiation Sciences, Oncology; 34Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden; Departments of 35Obstetrics and Gynecology, 36Population Health and Environmental Medicine, New York University School of Medicine, New York; 37Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, USA; 38Italian Institute for Genomic Medicine (IIGM), Torino, Italy; 39Centre de Recherche en Epidemiologie et Santé des Populations (EESP), UMR1018 Inserm, Faculté de Médecine, Université Paris-Saclay, Villejuif, France

†These authors contributed equally as last authors.

Correspondence to: Dr Paul Brennan, Genetic Epidemiology Group, International Agency for Research on Cancer (IARC-WHO), 150 cours Albert Thomas, 69008 Lyon, France. Tel: +33-4-72-73-85-33; E-mail: gep@iarc.fr

‡These authors contributed equally as last authors.

Background: There is observational evidence suggesting that high vitamin D concentrations may protect against lung cancer.

To investigate this hypothesis in detail, we measured circulating vitamin D concentrations in prediagnostic blood from 20 cohorts participating in the Lung Cancer Cohort Consortium (LC3).

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Patients and methods: The study included 5313 lung cancer cases and 5313 controls. Blood samples for the cases were collected, on average, 5 years before lung cancer diagnosis. Controls were individually matched to the cases by cohort, sex, age, race/ethnicity, date of blood collection, and smoking status in five categories. Liquid chromatography coupled with tandem mass spectrometry was used to separately analyze 25-hydroxyvitamin D2 [25(OH)D2] and 25-hydroxyvitamin D3 [25(OH)D3] and their concentrations were combined to give an overall measure of 25(OH)D. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for 25(OH)D as both continuous and categorical variables.

Results: Overall, no apparent association between 25(OH)D and risk of lung cancer was observed (multivariable adjusted OR for a doubling in concentration: 0.98, 95% CI: 0.91, 1.06). Similarly, we found no clear evidence of interaction by cohort, sex, age, smoking status, or histology.

Conclusion: This study did not support an association between vitamin D concentrations and lung cancer risk.

Key words: serum 25-hydroxyvitamin D, vitamin D, lung cancer, case–control, prospective, consortium

Introduction

Lung cancer is the most common cause of cancer death worldwide, accounting for over 20% of all cancer deaths [1]. Although avoidance of tobacco consumption remains the most important strategy for lung cancer prevention, a substantial proportion of lung cancer cases occur among former smokers, especially in countries where tobacco cessation campaigns have been successful. Identifying additional strategies to reduce lung cancer risk would be of particular relevance for high risk groups such as former smokers, and could have a substantial public health impact.

There is evidence that higher circulating vitamin D concentrations may reduce the risk of developing lung cancer [2, 3]. Vitamin D is produced primarily in the skin after exposure to ultraviolet B (UVB) radiation from sunlight. A secondary source of vitamin D is through diet or via dietary supplements [4]. Vitamin D is subsequently hydroxylated in the liver to form 25-hydroxyvitamin D [25(OH)D], the major circulating metabolite of vitamin D, which is then converted into its active form (1,25-dihydroxyvitamin D) in the kidneys and other tissues [5]. The necessity of adequate concentrations of vitamin D for bone health is well known [6], and vitamin D has also been implicated in the development of several cancers, particularly colorectal cancer [7, 8]. As reported in two meta-analyses, a number of prospective cohort and nested case–control studies have examined vitamin D concentrations, measured as 25(OH)D in blood samples, in terms of risk of lung cancer. In the first meta-analysis, pooled results from nine prospective studies reported a 17% decrease in lung cancer risk between participants with ‘high’ and ‘low’ concentrations of 25(OH)D [2]. The second meta-analysis reported similar results, although 10 of the studies were included in the first meta-analysis [2]. Pooled results from the second meta-analysis showed a nonlinear inverse association between 25(OH)D and lung cancer risk [3].

While these meta-analyses are informative, they are clearly constrained by the manner in which results are reported in the literature, and cannot account for variation that may occur between studies, including use of different laboratories for measurement of vitamin D. In order to provide a more definitive answer to the role of circulating vitamin D and risk of lung cancer, we conducted a pooled analysis of 25(OH)D concentrations in 5313 case–control pairs from 20 cohorts within the Lung Cancer Cohort Consortium (LC3).

Methods

The LC3 was established in 2009 as a project within the US National Cancer Institute (NCI) Cohort Consortium as a coordinated large-scale effort to study the role of B-vitamins in lung cancer [9]. Inclusion criteria for participating cohorts included the occurrence of at least 200 incident lung cancer cases with baseline questionnaire data and either plasma or serum samples—typically cryopreserved at <80°C. Twenty cohorts fulfilled those criteria and agreed to participate in the LC3, resulting in a combined cohort population of over 2,000,000 participants from Asia, Australia, Europe, and North America. All cohorts are listed in supplementary Table S1, available at Annals of Oncology online, along with the numbers of cases and controls contributed. Brief details on design of the cohorts and their follow-up procedures are also provided in the supplementary materials, available at Annals of Oncology online.

Selection of cases and controls

Lung cancer cases were defined on the basis of the International Classification of Diseases for Oncology, Second Edition (ICD-O-2), and included all invasive cancers coded as C34.0–C34.9. Altogether, 11,999 incident lung cancer cases with prediagnostic blood samples were identified from the participating cohorts. We selected a total of 5,545 lung cancer cases for subsequent blood based analysis, and to optimize the statistical power in smoking stratified risk analysis, never and former smoking cases were oversampled. For each case, one control was randomly chosen from risk sets consisting of all cohort members alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were cohort, sex, date of birth (<1 year, >1 year since quitting), and light and heavy smokers among current smokers (<10 cigarettes per day). After excluding cases who were not correctly matched on smoking status (n = 124 cases), who had insufficient blood samples (n = 42), or had a revised date of diagnosis before blood draw (n = 13), a total of 5,364 lung cancer case–control pairs remained eligible for analysis. Further exclusion of 51 participants whose matched pair was missing a 25(OH)D value resulted in a final set of 5,313 matched case–control pairs.

Biochemical analyses

Vitamin D analyses were conducted as part of a coordinated laboratory analysis along with a panel of 40 other biomarkers, focused primarily on B-vitamins and other biomarkers that are involved in the one carbon metabolism pathway [9]. Blood samples from all cases and controls were sent on dry ice to the Bevital AS laboratory (Bergen, Norway, www.bevital.no). Liquid chromatography coupled with tandem mass spectrometry was used to separately analyze 25(OH)D2 and 25(OH)D3 [10]. The limit of detection was 3.3 nmol/l, and within-day and between-day coefficients

of variation ranged from 4.4% to 8.2%. Circulating cotinine was also assessed with liquid chromatography coupled with tandem mass spectrometry. The limit of detection was 1 nmol/l, and the within-day and between-day coefficients of variation ranged from 2% to 6%. The laboratory is Vitamin D External Quality Assessment Scheme–certified (DEQAS, London, UK, www.deqas.org).

Statistical analysis

We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for 25(OH)D as both continuous and categorical variables. For categorical analyses, 25(OH)D was grouped according to the quartiles of its distribution among control participants, as well as an alternative grouping with extreme and moderate deficiency (<25 nmol/l) as the reference category. For continuous analyses, 25(OH)D was log-transformed, so ORs correspond to the expected fold-change in odds of lung cancer for a doubling in 25(OH)D concentration. All models were adjusted for circulating cotinine in four groups, defined by quartiles of cotinine among current smoking participants. We investigated potential interactions between 25(OH)D and sex, smoking status, cohort region, age at baseline, body mass index (kg/m²), time between blood draw and lung cancer diagnosis, as well as histological subtype. These analyses were conducted using R version 3.3.2 [11].

Because 25(OH)D is strongly affected by exposure to UVB radiation, we used season-adjusted concentrations. We modeled seasonal variation of log-transformed 25(OH)D using two pairs of sine and cosine functions of day of blood collection in a hierarchical linear regression model, allowing model parameters to vary by cohort. The use of trigonometric functions allows

Table 1. Distribution of demographic and individual characteristics of cases and controls, overall and by continent

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Case</th>
<th>Control</th>
<th>Case</th>
<th>Control</th>
<th>Case</th>
<th>Control</th>
<th>Case</th>
<th>Control</th>
<th>Case</th>
<th>Control</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>5313</td>
<td>100</td>
<td>5313</td>
<td>100</td>
<td>1728</td>
<td>100</td>
<td>1728</td>
<td>100</td>
<td>353</td>
<td>100</td>
<td>353</td>
<td>100</td>
</tr>
<tr>
<td>Men</td>
<td>2892</td>
<td>54</td>
<td>2892</td>
<td>54</td>
<td>714</td>
<td>40</td>
<td>714</td>
<td>40</td>
<td>142</td>
<td>41</td>
<td>142</td>
<td>41</td>
</tr>
<tr>
<td>Women</td>
<td>2421</td>
<td>46</td>
<td>2421</td>
<td>46</td>
<td>1014</td>
<td>56</td>
<td>1014</td>
<td>56</td>
<td>211</td>
<td>60</td>
<td>211</td>
<td>60</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>1285</td>
<td>24</td>
<td>1285</td>
<td>24</td>
<td>506</td>
<td>30</td>
<td>506</td>
<td>30</td>
<td>194</td>
<td>55</td>
<td>194</td>
<td>55</td>
</tr>
<tr>
<td>Former</td>
<td>1517</td>
<td>29</td>
<td>1517</td>
<td>29</td>
<td>768</td>
<td>45</td>
<td>768</td>
<td>45</td>
<td>255</td>
<td>45</td>
<td>255</td>
<td>45</td>
</tr>
<tr>
<td>Age at recruitment (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[17, 55)</td>
<td>1547</td>
<td>29</td>
<td>1547</td>
<td>29</td>
<td>644</td>
<td>40</td>
<td>644</td>
<td>40</td>
<td>176</td>
<td>30</td>
<td>176</td>
<td>30</td>
</tr>
<tr>
<td>[55, 60)</td>
<td>995</td>
<td>19</td>
<td>995</td>
<td>19</td>
<td>366</td>
<td>21</td>
<td>366</td>
<td>21</td>
<td>66</td>
<td>18</td>
<td>66</td>
<td>18</td>
</tr>
<tr>
<td>[60, 65)</td>
<td>1247</td>
<td>23</td>
<td>1247</td>
<td>23</td>
<td>427</td>
<td>25</td>
<td>427</td>
<td>25</td>
<td>125</td>
<td>35</td>
<td>125</td>
<td>35</td>
</tr>
<tr>
<td>[65, 86]</td>
<td>1524</td>
<td>29</td>
<td>1524</td>
<td>29</td>
<td>506</td>
<td>29</td>
<td>506</td>
<td>29</td>
<td>145</td>
<td>35</td>
<td>145</td>
<td>35</td>
</tr>
</tbody>
</table>

Table 2. Characteristics of the lung cancer cases, overall and by continent

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Asia</th>
<th>Australia</th>
<th>Europe</th>
<th>United States</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cell</td>
<td>173</td>
<td>3</td>
<td>31</td>
<td>15</td>
<td>112</td>
</tr>
<tr>
<td>Small cell</td>
<td>490</td>
<td>9</td>
<td>47</td>
<td>10</td>
<td>243</td>
</tr>
<tr>
<td>Squamous cell</td>
<td>835</td>
<td>16</td>
<td>67</td>
<td>17</td>
<td>288</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>2029</td>
<td>38</td>
<td>152</td>
<td>43</td>
<td>1028</td>
</tr>
<tr>
<td>Other</td>
<td>590</td>
<td>11</td>
<td>53</td>
<td>15</td>
<td>293</td>
</tr>
<tr>
<td>Unknown/missing</td>
<td>1196</td>
<td>23</td>
<td>3</td>
<td>3</td>
<td>433</td>
</tr>
<tr>
<td>Time to diagnosis (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[0, 2)</td>
<td>587</td>
<td>11</td>
<td>35</td>
<td>10</td>
<td>244</td>
</tr>
<tr>
<td>[2, 5]</td>
<td>1333</td>
<td>25</td>
<td>45</td>
<td>13</td>
<td>735</td>
</tr>
<tr>
<td>[5, 10]</td>
<td>1622</td>
<td>31</td>
<td>101</td>
<td>29</td>
<td>663</td>
</tr>
<tr>
<td>[10, 36]</td>
<td>1588</td>
<td>30</td>
<td>172</td>
<td>49</td>
<td>572</td>
</tr>
</tbody>
</table>
estimation of the periodic variation in 25(OH)D$_3$ and produces smooth predictions with no artificial discontinuities from season to season, or year to year. We included two pairs of sine and cosine functions in the models because the inclusion of additional terms did not improve model fit, nor did it substantially affect parameter estimates in the final models. For each participant, season-adjusted 25(OH)D was calculated by adding or subtracting the expected seasonal deviation from the mean 25(OH)D$_3$ concentration based on the day of blood draw, and adding the 25(OH)D$_2$ concentration. These Bayesian hierarchical models were fitted using Stan version 2.9.1 via Rstan [12, 13].

Results

Demographic and baseline characteristics of the 5313 case–control pairs are presented in Table 1, both overall and by geographic region. Participants from the United States had higher circulating concentrations of total 25(OH)D on average compared with participants from Asia, or Europe and Australia. Table 2 presents the histological subtype of lung cancer cases, as well as the distribution of time between baseline blood collection and diagnosis.

Figure 1 shows the observed 25(OH)D concentrations by day of blood draw, as well as the model-estimated mean concentrations, for each cohort separately. Figure 2 shows the season-adjusted and observed 25(OH)D concentrations. ORs for risk of lung cancer by category of 25(OH)D concentration, as well as for a doubling in concentration, are presented in Table 3. No apparent dose–response association was observed between 25(OH)D and risk of lung cancer overall (OR for a doubling in concentration: 0.98, 95% CI: 0.91, 1.06), nor for specific categories of 25(OH)D.
concentration. Further, we found little evidence of interaction by any demographic factor or individual participant characteristic (Figure 3). There was some evidence of an inverse association between 25(OH)D and risk of lung cancer in the European cohorts (OR for a doubling in concentration 0.75, 95% CI: 0.61, 0.92), but statistical evidence for an interaction was weak \( (P = 0.05) \). Cohort-specific estimates suggest that any association among European participants was driven by MDCS and NSHDS, the two Swedish cohorts), although we found no overall evidence of interaction by cohort (Figure 4). Sensitivity analyses in which we excluded circulating cotinine from the models provided similar results to the fully adjusted models (supplementary Figure S1, available at Annals of Oncology online). Using 25(OH)D3 only also yielded similar results (supplementary Figure S2, available at Annals of Oncology online).

**Discussion**

Based on a comprehensive analysis of over 5000 case–control pairs from 20 prospective cohort studies, we found no association between circulating vitamin D concentrations and risk of subsequent lung cancer diagnosis.

Our results contrast with the two previous meta-analyses that reported inverse associations between circulating vitamin D concentrations and lung cancer risk \[2, 3\]. As always with meta-analyses, it is possible that the collection of published studies does not represent the total sum of all conducted studies, whereby studies with null results are more likely to go unpublished. Although neither study reported evidence for publication bias, we note that the results were strongly influenced by one study from Copenhagen with approximately 10 000 participants and 507 incident lung cancer cases with 25-year follow-up \[14\], accounting for 65% of the association reported by Zhang et al \[2\]. The second meta-analysis by Chen et al. was based on 10 cohorts \[3\], but there was considerable overlap between included studies in both the Chan and Zhang meta-analyses, and both included the aforementioned Copenhagen cohort study \[14\]. It should therefore be no surprise that the pooled estimates across
these two meta-analyses suggest a similar inverse association with risk.

Median 25(OH)D concentrations in the Copenhagen cohort were 41 nmol/l overall, and 37 nmol/l among those who went on to develop a tobacco-related cancer, similar to approximately the first fourth of 25(OH)D for the LC3 cohorts overall. It is of interest that Afzal et al. also observed significant associations with vitamin D for other tobacco related cancers including head and neck cancer, bladder and kidney cancer in the Copenhagen cohort [15]. Given the limited adjustment for tobacco use in the Copenhagen cohort (i.e., pack-years only), and the strong association between vitamin D concentrations and smoking intensity, this would suggest the possibility that residual confounding by smoking may explain at least some of the observed inverse associations with vitamin D concentrations with lung cancer risk, as well as with other tobacco related cancers in that study [14]. In our study, estimates were similar in models that were not adjusted for circulating cotinine, indicating that residual confounding is unlikely to fully explain these discrepant results. Further, the estimates from the Copenhagen cohort are consistent with the estimates that we present for the two cohorts from Sweden. The absence of evidence supporting an interaction by cohort, however, suggests that any observed inverse associations in our study are likely to be consistent with sampling variability.

Our results, based on over 5000 incident lung cancer cases and 5000 individually matched controls, clearly point to a lack of association for risk of lung cancer across a broad range of vitamin D concentrations. Our study has several strengths including centralized biochemical analysis of prediagnostic vitamin D and detailed control for tobacco exposure among current smokers using cotinine concentrations, an objective measure of recent tobacco exposure. There is a lack of consensus surrounding terminology and vitamin D concentrations that are considered adequate or deficient. The 2011 US Institute of Medicine report considers individuals with concentrations below 30 nmol/l at risk of deficiency, and those below 50 nmol/l at risk of inadequacy [15]. An alternative definition considers concentrations below 50 nmol/l as deficient, with further subclassifications of...
mild (25–50 nmol/l), moderate (12.5–25 nmol/l), and severe (<12.5 nmol/l) deficiency [16]. Our reference exposure group included participants with vitamin D concentrations between 7 and 41 nmol/l, and therefore included a broad range of persons with vitamin D deficiency or inadequacy. Even when we further restricted the reference category to include only those participants with vitamin D concentrations below 25 nmol/l, we found no evidence for an association for adequate vitamin D concentrations with lower lung cancer risk.

Conclusion

In summary, we found no overall evidence for an association between circulating concentrations of vitamin D and risk of lung cancer in 20 prospective cohort studies from the Asia, Australia, and Europe, and the United States, but some suggestion of an inverse association in two Swedish cohorts. In light of this, we consider that vitamin D supplementation is unlikely to prove broadly effective for the primary prevention of lung cancer. Ongoing cancer prevention trials testing vitamin D supplements may eventually provide additional evidence on whether or not increases in vitamin D concentrations translate to reductions in lung cancer risks or not.

Acknowledgements

We thank the study participants and LC3 consortium members for their contributions in making this study possible. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf.

Funding

The Lung Cancer Cohort Consortium (LC3) was supported by a grant from the National Cancer Institute, National Institutes of Health (grant number 1U01CA155340-01) and National Health and Medical Research Council Australia (grant number 1050198). DCM was supported by an IARC/Australia Fellowship funded by Cancer Council Australia and a Cancer Research UK Population Research Fellowship (no grant numbers apply). TLL was supported by The Research Council of Norway (grant number 267776/H10). The work of TLL presented in this paper was undertaken during a postdoctoral placement at the International Agency for Research on Cancer, within the framework of an agreement between the Research Council of Norway and the Norwegian University of Science and Technology. The funding organizations had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN26820160002C, HHSN26820160003C, and HHS.
N268201600004C. Shanghai Womens Health Study was supported by R37 CA070867 and UM1 CA182910 and Shanghai Mens Health Study by R01 CA082729 and UM1 CA173640 from the US National Cancer Institute.

Disclosure

PMU and ØM report that they are members of the steering board of the nonprofit Foundation to Promote Research Into Functional Vitamin B12 Deficiency. All remaining authors have declared no conflicts of interest.

References